In vivo CAR-T gen 1.0 is unlikely to overcome solid tumors without a way to safely boost potency.

Armoring can increase activity, but without tunability toxicity is likely (e.g. PSMA CAR-T/tgfbr2)

Our Solution

Tunable armored in vivo CAR-T that is extremely efficient to transduce and manufacture

Naturally this can also be applied to heme oncology and I&I

Our Team

World-class team developing the next generation of in vivo CAR-T cell therapeutics

Ton Schumacher

Ton Schumacher

Founder and Advisor

Third Rock Ventures

Frank Stegmeier

Frank Stegmeier

President

Ali Can Sahillioglu

Black and white photo of a man with glasses smiling.

Founder and Chief Technology Officer

Ali Can Sahillioglu

Thomas Pertel

VP; Head of Preclinical Development

Close-up portrait of a middle-aged man with short, light-colored hair, blue eyes, and a slight smile, wearing a black jacket over a white shirt with a pattern.

CxO

Jon Terrett

Colorful text that reads "Curie.Bio" in a gradient from purple to pink to orange.

PV Sivakumar

CSO Co-Pilot

RheoCAR-T™ Platform

A proprietary platform enabling Cell Therapy 3.0

Illustration of a person with in vivo CAR-T shot near their arm.

Scalable

Novel T cell targeting to enable safe and efficient in vivo CAR-T engineering with a single dose‍ ‍

A sleek black sports car with exposed engine components and large rear wing, emitting flames from its exhaust pipes, on an open road at sunset.

Powerful

Modular platform for integrating diverse potency-enhancing payloads enabling deep and durable responses

Car speedometer showing 200 km/h with the needle pointing to 200 and a red zone indicating high speed.

Controllable

Tight CAR and payload control with low dose of FDA-approved small molecule

RheoBrick™ ON-switch

Tuning system to enable armoring

Diagram of RheoBrick showing three scenarios: no lenalidomide, no antigen, no cargo expression; no lenalidomide, no antigen, cargo not expressed; lenalidomide, antigen, cargo expressed. Each scenario illustrates tumor cell interaction with CAR T cells, indicating CAR signaling suppression or activation, and drug-induced degradation.

Proprietary degron functional in vivo at sub clinical doses of lenalidomide

IL-15 armoring

More potent and tunable CAR-Ts

A legend explaining different conditions using colored shapes: gray circle for control with vehicle, gray square for control with lenalidomide, blue circle for conv CAR-T with vehicle, blue square for conv CAR-T with lenalidomide, red circle for RheoCAR-T/IL15 with vehicle, and red square for RheoCAR-T/IL15 with lenalidomide.

Our publications

Patent families

1) WO2021080427A1: CHIMERIC POLYPEPTIDE FOR REGULATING IMMUNE CELLS

2) WO2023177296A1: Zinc finger degron sequences

3) WO2024117904A1: Receptor- and drug-dependent regulated on-site production of biologicals.

4) WO2025248464A3: Loop reinforcement expression system for improved cell therapy products.

Papers

1) CRASH-IT switch enables reversible and dose-dependent control of TCR and CAR T-cell function. Cancer Immunology Research

2) Multimodular Optimization of Chemically Regulated T Cell Switches Demonstrates Flexible and Interchangeable Nature of Immune Cell Signaling Domains. Human Gene Therapy

3) Safety switches for adoptive cell therapy. Current Opinion in Immunology